181 related articles for article (PubMed ID: 3659096)
21. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
22. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
23. Modulation of muscarinic cholinergic receptor affinity for antagonists in rat heart.
Martin MW; Smith MM; Harden TK
J Pharmacol Exp Ther; 1984 Aug; 230(2):424-30. PubMed ID: 6379149
[TBL] [Abstract][Full Text] [Related]
24. Regional differences in the coupling of muscarinic receptors to inositol phospholipid hydrolysis in guinea pig brain.
Fisher SK; Bartus RT
J Neurochem; 1985 Oct; 45(4):1085-95. PubMed ID: 2411866
[TBL] [Abstract][Full Text] [Related]
25. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
26. The effects of chronic oxotremorine treatment on spatial learning and tolerance development in mice.
Wehner JM; Upchurch M
Pharmacol Biochem Behav; 1989 Feb; 32(2):543-51. PubMed ID: 2727016
[TBL] [Abstract][Full Text] [Related]
27. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
Ladner CJ; Lee JM
Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152
[TBL] [Abstract][Full Text] [Related]
28. Muscarinic receptor subtypes and sexual behavior in female rats.
Dohanich GP; McMullan DM; Cada DA; Mangum KA
Pharmacol Biochem Behav; 1991 Jan; 38(1):115-24. PubMed ID: 1708147
[TBL] [Abstract][Full Text] [Related]
29. Characterization of M1- and M2-muscarinic receptors in calf retina membranes.
Vanderheyden P; Ebinger G; Vauquelin G
Vision Res; 1988; 28(2):247-50. PubMed ID: 3414010
[TBL] [Abstract][Full Text] [Related]
30. Sialic acid residues as catalysts for M2-muscarinic agonist-receptor interactions.
Haddad EB; Landry Y; Gies JP
Mol Pharmacol; 1990 May; 37(5):682-8. PubMed ID: 1692606
[TBL] [Abstract][Full Text] [Related]
31. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.
Gillard M; Waelbroeck M; Christophe J
Mol Pharmacol; 1987 Jul; 32(1):100-8. PubMed ID: 3600611
[TBL] [Abstract][Full Text] [Related]
32. [3H]AF-DX 116 labels subsets of muscarinic cholinergic receptors in rat brain and heart.
Wang JX; Roeske WR; Gulya K; Wang W; Yamamura HI
Life Sci; 1987 Oct; 41(14):1751-60. PubMed ID: 3657382
[TBL] [Abstract][Full Text] [Related]
33. Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
el-Fakahany EE; Ramkumar V; Lai WS
J Pharmacol Exp Ther; 1986 Aug; 238(2):554-63. PubMed ID: 3755473
[TBL] [Abstract][Full Text] [Related]
34. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.
Watson M; Yamamura HI; Roeske WR
Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111
[TBL] [Abstract][Full Text] [Related]
35. Differential interactions of muscarinic drugs with binding sites of [3H]pirenzepine and [3H]quinuclidinyl benzilate in rat brain tissue.
Tonnaer JA; van Vugt MA; de Boer T; de Graaf JS
Life Sci; 1987 May; 40(20):1981-7. PubMed ID: 3573989
[TBL] [Abstract][Full Text] [Related]
36. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
37. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
Forray C; el-Fakahany EE
Mol Pharmacol; 1990 Jun; 37(6):893-902. PubMed ID: 2163015
[TBL] [Abstract][Full Text] [Related]
38. Genotype influences the development of tolerance to nicotine in the mouse.
Marks MJ; Campbell SM; Romm E; Collins AC
J Pharmacol Exp Ther; 1991 Oct; 259(1):392-402. PubMed ID: 1920127
[TBL] [Abstract][Full Text] [Related]
39. In vivo modulation of the number of muscarinic receptors in rat brain by cholinergic ligands.
Ben-Barak J; Gazit H; Silman I; Dudai Y
Eur J Pharmacol; 1981 Aug; 74(1):73-81. PubMed ID: 7318895
[TBL] [Abstract][Full Text] [Related]
40. Different agonist binding properties of M1 and M2 muscarinic receptors in calf brain cortex membranes.
Vanderheyden P; Ebinger G; Vauquelin G
Biochem Pharmacol; 1987 Dec; 36(23):4119-24. PubMed ID: 3689439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
